New England Journal of Medicine· 2020Q1· Clinical trial

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

Giancarlo Agnelli, Cecilia Becattini, Guy Meyer, Andrés J. Muñoz Martín et al.

1,044citations
Q1SCImago
2020year

Short summary

Oral apixaban proved noninferior to subcutaneous dalteparin in treating cancer-associated venous thromboembolism, with a similar risk of major bleeding.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Internal Medicine

Internal MedicineMedicine